Annual CFO
-$8.78 M
-$3.53 M-67.20%
31 December 2023
Summary:
Sunshine Biopharma annual cash flow from operations is currently -$8.78 million, with the most recent change of -$3.53 million (-67.20%) on 31 December 2023. During the last 3 years, it has fallen by -$8.12 million (-1235.03%). SBFMW annual CFO is now -280973.38% below its all-time high of -$3122.00, reached on 31 July 2007.SBFMW Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.36 M
+$3.22 M+70.27%
30 September 2024
Summary:
Sunshine Biopharma quarterly cash flow from operations is currently -$1.36 million, with the most recent change of +$3.22 million (+70.27%) on 30 September 2024. Over the past year, it has dropped by -$903.67 thousand (-197.61%). SBFMW quarterly CFO is now -149291.44% below its all-time high of -$911.00, reached on 31 January 2009.SBFMW Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$11.81 M
-$903.67 K-8.28%
30 September 2024
Summary:
Sunshine Biopharma TTM cash flow from operations is currently -$11.81 million, with the most recent change of -$903.67 thousand (-8.28%) on 30 September 2024. Over the past year, it has dropped by -$3.48 million (-41.78%). SBFMW TTM CFO is now -168665.34% below its all-time high of -$7000.00, reached on 31 October 2007.SBFMW TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SBFMW Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -67.2% | -197.6% | -41.8% |
| 3 y3 years | -1235.0% | -126.5% | -508.7% |
| 5 y5 years | -1611.2% | -1472.7% | -2340.8% |
SBFMW Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1235.0% | at low | -336.1% | +70.3% | -545.9% | at low |
| 5 y | 5 years | -1669.9% | at low | -4285.4% | +70.3% | -3933.7% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +70.3% | <-9999.0% | at low |
Sunshine Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.36 M(-70.3%) | -$11.81 M(+8.3%) |
| June 2024 | - | -$4.58 M(+43.7%) | -$10.91 M(+7.9%) |
| Mar 2024 | - | -$3.19 M(+18.4%) | -$10.11 M(+15.2%) |
| Dec 2023 | -$8.78 M(+67.2%) | -$2.69 M(+488.2%) | -$8.78 M(+5.3%) |
| Sept 2023 | - | -$457.29 K(-87.9%) | -$8.33 M(-7.4%) |
| June 2023 | - | -$3.78 M(+104.2%) | -$9.00 M(+55.3%) |
| Mar 2023 | - | -$1.85 M(-17.6%) | -$5.79 M(+10.4%) |
| Dec 2022 | -$5.25 M(+186.9%) | -$2.25 M(+99.9%) | -$5.25 M(+58.4%) |
| Sept 2022 | - | -$1.12 M(+95.8%) | -$3.31 M(+18.7%) |
| June 2022 | - | -$573.80 K(-56.0%) | -$2.79 M(-1.6%) |
| Mar 2022 | - | -$1.30 M(+317.9%) | -$2.84 M(+55.0%) |
| Dec 2021 | -$1.83 M(+178.3%) | -$312.11 K(-48.1%) | -$1.83 M(-5.7%) |
| Sept 2021 | - | -$600.81 K(-2.9%) | -$1.94 M(+32.9%) |
| June 2021 | - | -$618.85 K(+108.1%) | -$1.46 M(+58.1%) |
| Mar 2021 | - | -$297.36 K(-29.8%) | -$923.62 K(+40.5%) |
| Dec 2020 | -$657.30 K(+32.6%) | -$423.67 K(+251.4%) | -$657.30 K(+81.8%) |
| Sept 2020 | - | -$120.58 K(+47.0%) | -$361.47 K(+10.4%) |
| June 2020 | - | -$82.02 K(+164.3%) | -$327.43 K(+11.8%) |
| Mar 2020 | - | -$31.03 K(-75.7%) | -$292.87 K(-40.9%) |
| Dec 2019 | -$495.80 K(-3.3%) | -$127.84 K(+47.7%) | -$495.80 K(+2.4%) |
| Sept 2019 | - | -$86.54 K(+82.3%) | -$484.01 K(-3.5%) |
| June 2019 | - | -$47.46 K(-79.7%) | -$501.33 K(-13.3%) |
| Mar 2019 | - | -$233.96 K(+101.6%) | -$578.31 K(+12.8%) |
| Dec 2018 | -$512.81 K(-5.7%) | -$116.05 K(+11.7%) | -$512.81 K(-15.4%) |
| Sept 2018 | - | -$103.86 K(-16.5%) | -$606.24 K(-6.8%) |
| June 2018 | - | -$124.44 K(-26.1%) | -$650.57 K(+7.7%) |
| Mar 2018 | - | -$168.46 K(-19.6%) | -$603.94 K(+11.1%) |
| Dec 2017 | -$543.52 K(+73.0%) | -$209.48 K(+41.4%) | -$543.52 K(+48.8%) |
| Sept 2017 | - | -$148.19 K(+90.4%) | -$365.23 K(+30.4%) |
| June 2017 | - | -$77.81 K(-28.0%) | -$280.04 K(-17.8%) |
| Mar 2017 | - | -$108.04 K(+246.3%) | -$340.62 K(+8.4%) |
| Dec 2016 | -$314.18 K | -$31.19 K(-50.5%) | -$314.18 K(-49.9%) |
| Sept 2016 | - | -$62.99 K(-54.5%) | -$626.90 K(-6.4%) |
| June 2016 | - | -$138.40 K(+69.6%) | -$669.75 K(-19.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$81.60 K(-76.3%) | -$836.25 K(-3.6%) |
| Dec 2015 | -$867.64 K(+61.1%) | -$343.92 K(+224.9%) | -$867.64 K(+22.0%) |
| Sept 2015 | - | -$105.84 K(-65.3%) | -$711.44 K(+4.1%) |
| June 2015 | - | -$304.89 K(+169.8%) | -$683.65 K(+21.9%) |
| Mar 2015 | - | -$113.00 K(-39.8%) | -$560.81 K(+4.1%) |
| Dec 2014 | -$538.60 K(-4.6%) | -$187.71 K(+140.5%) | -$538.60 K(+37.9%) |
| Sept 2014 | - | -$78.05 K(-57.1%) | -$390.63 K(-1.9%) |
| June 2014 | - | -$182.05 K(+100.5%) | -$398.22 K(+26.2%) |
| Mar 2014 | - | -$90.78 K(+128.4%) | -$315.46 K(-44.1%) |
| Dec 2013 | -$564.40 K(+43.6%) | -$39.75 K(-53.6%) | -$564.40 K(-19.1%) |
| Sept 2013 | - | -$85.64 K(-13.7%) | -$697.43 K(-9.7%) |
| June 2013 | - | -$99.28 K(-70.8%) | -$772.11 K(+10.6%) |
| Mar 2013 | - | -$339.72 K(+96.6%) | -$698.02 K(+77.6%) |
| Dec 2012 | -$393.05 K(+32.2%) | -$172.78 K(+7.8%) | -$393.05 K(+16.3%) |
| Sept 2012 | - | -$160.33 K(+536.4%) | -$338.06 K(+14.2%) |
| June 2012 | - | -$25.19 K(-27.5%) | -$296.10 K(+2.9%) |
| Mar 2012 | - | -$34.76 K(-70.5%) | -$287.73 K(-3.2%) |
| Dec 2011 | -$297.30 K(-14.6%) | -$117.78 K(-0.5%) | -$297.30 K(-29.9%) |
| Sept 2011 | - | -$118.37 K(+603.7%) | -$423.88 K(+35.1%) |
| June 2011 | - | -$16.82 K(-62.1%) | -$313.65 K(+1.3%) |
| Mar 2011 | - | -$44.33 K(-81.9%) | -$309.68 K(-11.1%) |
| Dec 2010 | -$348.32 K(+1165.1%) | -$244.36 K(+2900.8%) | -$348.32 K(+235.0%) |
| Sept 2010 | - | -$8143.00(-36.6%) | -$103.97 K(-81.6%) |
| June 2010 | - | -$12.85 K(-84.5%) | -$564.98 K(+2.1%) |
| Mar 2010 | - | -$82.98 K(-82.3%) | -$553.63 K(+16.9%) |
| Oct 2009 | - | -$469.15 K(>+9900.0%) | -$473.49 K(+4530.7%) |
| July 2009 | - | -$1499.00(-22.2%) | -$10.22 K(-35.1%) |
| Apr 2009 | - | -$1927.00(+111.5%) | -$15.76 K(-35.2%) |
| Jan 2009 | - | -$911.00(-84.5%) | -$24.32 K(-8.0%) |
| Oct 2008 | - | -$5888.00(-16.2%) | -$26.42 K(-4.0%) |
| July 2008 | -$27.53 K(+781.9%) | -$7029.00(-33.0%) | -$27.53 K(+34.3%) |
| Apr 2008 | - | -$10.49 K(+247.9%) | -$20.50 K(+104.7%) |
| Jan 2008 | - | -$3015.00(-56.9%) | -$10.02 K(+43.1%) |
| Oct 2007 | - | -$7000.00 | -$7000.00 |
| July 2007 | -$3122.00 | - | - |
FAQ
- What is Sunshine Biopharma annual cash flow from operations?
- What is the all time high annual CFO for Sunshine Biopharma?
- What is Sunshine Biopharma annual CFO year-on-year change?
- What is Sunshine Biopharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly CFO year-on-year change?
- What is Sunshine Biopharma TTM cash flow from operations?
- What is the all time high TTM CFO for Sunshine Biopharma?
- What is Sunshine Biopharma TTM CFO year-on-year change?
What is Sunshine Biopharma annual cash flow from operations?
The current annual CFO of SBFMW is -$8.78 M
What is the all time high annual CFO for Sunshine Biopharma?
Sunshine Biopharma all-time high annual cash flow from operations is -$3122.00
What is Sunshine Biopharma annual CFO year-on-year change?
Over the past year, SBFMW annual cash flow from operations has changed by -$3.53 M (-67.20%)
What is Sunshine Biopharma quarterly cash flow from operations?
The current quarterly CFO of SBFMW is -$1.36 M
What is the all time high quarterly CFO for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly cash flow from operations is -$911.00
What is Sunshine Biopharma quarterly CFO year-on-year change?
Over the past year, SBFMW quarterly cash flow from operations has changed by -$903.67 K (-197.61%)
What is Sunshine Biopharma TTM cash flow from operations?
The current TTM CFO of SBFMW is -$11.81 M
What is the all time high TTM CFO for Sunshine Biopharma?
Sunshine Biopharma all-time high TTM cash flow from operations is -$7000.00
What is Sunshine Biopharma TTM CFO year-on-year change?
Over the past year, SBFMW TTM cash flow from operations has changed by -$3.48 M (-41.78%)